Healius share price unnaturally influenced ?, page-10

Lost for words.!
HLS - HEALIUS LIMITED
Citi rates HLS as Neutral (3) - Citi believes subdued September-quarter Medicare data, combined with trading updates from Integral Diagnostics ((IDX)) and Australian Clinical Labs ((ACL)), augur poorly for Healius's earnings.The potential for lower pathology volumes and higher imaging labour costs concern Citi, which spies a risk to consensus forecasts.The broker's FY24 earnings (EBIT) forecast sit -7% below consensus. EPS forecasts are steady.Neutral rating retained. Target price falls to $2.15 from $3.Target price is $2.15 Current Price is $1.98 Difference: $0.17 If HLS meets the Citi target it will return approximately 9% (excluding dividends, fees and charges). Current consensus price target is $2.80, suggesting upside of 41.4%(ex-dividends)The company's fiscal year ends in June.Forecast for FY24:Citi forecasts a full year FY24 dividend of 0.00 cents and EPS of 6.60 cents . At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 30.00. How do these forecasts compare to market consensus projections?Current consensus EPS estimate is 7.0, implying annual growth of N/A. Current consensus DPS estimate is 2.8, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 28.3.Forecast for FY25:Citi forecasts a full year FY25 dividend of 5.60 cents and EPS of 11.20 cents . At the last closing share price the estimated dividend yield is 2.83%. At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.68. How do these forecasts compare to market consensus projections?Current consensus EPS estimate is 12.4, implying annual growth of 77.1%. Current consensus DPS estimate is 6.5, implying a prospective dividend yield of 3.3%. Current consensus EPS estimate suggests the PER is 16.0.Market Sentiment: 0.1All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources